ACTRN12611000186954尚未招募未知
Improving outcomes for haematological cancer patients receiving chemotherapy: a randomised controlled trial to assess the impact of a technology mediated nurse-led intervention
Peter MacCallum Cancer Centre0 个研究点目标入组 320 人开始时间: 2011年2月16日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 320
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Have a diagnosis of one of three haematological cancers (Hodgkin's lymphoma, Non-hodgkin's lymphoma or Chronic Lymphocytic Leukemia)
- •Be receiving four or more cycles of chemotherapy treatment in a day treatment unit
- •Be over 18 years of age
排除标准
- •Having a key cognitive psychological disorder as assessed by the treatmetn team
- •Unable to speak/read/write English
- •Participating in a clinical drug trial
研究者
相似试验
招募中
不适用
Bleeding in patients with hemato-oncological disease in relation to platelet function (BOP study)patients with hemato-oncological disease10002086NL-OMON47418Meander Medisch Centrum Amersfoort160
招募中
不适用
Evaluation of anti-SARS-CoV-2 antibody in patients with hematological diseases who receive treatment after vaccination.hematological diseasesJPRN-UMIN000052145Blood Disorders Center, Aiiku Hospital500
已完成
1 期
Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic TransplantationHematologic MalignanciesMultiple MyelomaNCT01460420Stichting European Myeloma Network49
已完成
2 期
Efficacy of Aprepitant for Hematology and Oncology.Hematological cancerJPRN-UMIN000005705Kyoto University Hospital,Department of Hematology and Oncology52
进行中（未招募）
2 期
Repurposed drugs to improve blood counts and reduce transfusions in myelodysplastic syndromesMyelodysplastic syndromesCancerISRCTN15563554niversity of Warwick120